Lead Product(s) : Mirodenafil
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : $770.0 million
Deal Type : Agreement
AriBio Licenses Exclusive Marketing Rights for AR1001 for Alzheimer’s Disease in China
Details : AriBio has concluded an exclusive distribution agreement with a Chinese pharmaceutical company for AR1001 (mirodenafil), an oral PDE5 inhibitor, for the treatment for Alzheimer's disease, in China.
Brand Name : AR1001
Molecule Type : Small molecule
Upfront Cash : $90.0 million
March 24, 2024
Lead Product(s) : Mirodenafil
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : $770.0 million
Deal Type : Agreement
LOOKING FOR A SUPPLIER?